Genomic Vision Société Anonyme
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company provides FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glas… Read more
Genomic Vision Société Anonyme (G09) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.485x
Based on the latest financial reports, Genomic Vision Société Anonyme (G09) has a cash flow conversion efficiency ratio of 0.485x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.34 Million) by net assets (€-2.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genomic Vision Société Anonyme - Cash Flow Conversion Efficiency Trend (2013–2022)
This chart illustrates how Genomic Vision Société Anonyme's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genomic Vision Société Anonyme Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genomic Vision Société Anonyme ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Giant Motorsports Inc
PINK:BZRD
|
0.085x |
|
SYROS PHARMAC.NEW DL-001
F:0S90
|
N/A |
|
Emmaus Life Sciences Inc
OTCQB:EMMA
|
-0.007x |
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
0.029x |
|
CL8 Holdings Ltd
AU:CL8
|
0.158x |
|
Taiton Resources Ltd
AU:T88
|
-0.020x |
|
Hopium SAS
PA:ALHPI
|
0.000x |
|
Societe Parisienne d’apports En Capital SPAC SA
PA:MHM
|
0.019x |
Annual Cash Flow Conversion Efficiency for Genomic Vision Société Anonyme (2013–2022)
The table below shows the annual cash flow conversion efficiency of Genomic Vision Société Anonyme from 2013 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €-1.29 Million | €-4.41 Million | 3.424x | +332.63% |
| 2021-12-31 | €3.07 Million | €-4.52 Million | -1.472x | -25.46% |
| 2020-12-31 | €3.12 Million | €-3.67 Million | -1.173x | +26.14% |
| 2019-12-31 | €3.23 Million | €-5.13 Million | -1.588x | -18.35% |
| 2018-12-31 | €4.17 Million | €-5.59 Million | -1.342x | +36.07% |
| 2017-12-31 | €3.76 Million | €-7.89 Million | -2.099x | -158.99% |
| 2016-12-31 | €10.04 Million | €-8.13 Million | -0.811x | -169.21% |
| 2015-12-31 | €18.38 Million | €-5.54 Million | -0.301x | -81.21% |
| 2014-12-31 | €22.70 Million | €-3.77 Million | -0.166x | -167.43% |
| 2013-12-31 | €982.00K | €242.00K | 0.246x | -- |